Showing results (91-100 of 150) with videos related to

Sort By:
Pageof 15
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 6, 2017
Patterns of failure in limited-stage small cell lung cancer: Implications of TNM stage for prophylactic cranial irradiationAbraham J Wu, Andrea Gillis, Amanda Foster, et al.
Annals of Surgery|November 20, 2020
Survival After Trimodality Therapy in Patients With Locally Advanced Esophagogastric Adenocarcinoma: Does Only a Complete Pathologic Response Matter?Smita Sihag, Tamar Nobel, Meier Hsu, et al.
Translational Lung Cancer Research|June 24, 2021
Complete disease remission in a TP53 and KRAS co-mutated brain oligometastatic lung cancer patient after immuno-chemotherapy and surgical resection: a case reportShuai Zhu, Shikang Zhao, Qian Zhang, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 23, 2021
Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumabMaria Thor, Annemarie F Shepherd, Isabel Preeshagul, et al.
Acta Oncologica (Stockholm, Sweden)|June 7, 2018
Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC)Donata von Reibnitz, Fauzia Shaikh, Abraham J Wu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 14, 2024
An 18F-FDG PET/CT and Mean Lung Dose Model to Predict Early Radiation Pneumonitis in Stage III Non-Small Cell Lung Cancer Patients Treated with Chemoradiation and ImmunotherapyMaria Thor, Chen Lee, Lian Sun, et al.
JAMA Network Open|January 5, 2023
Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patents with Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and DurvalumabEmily S Lebow, Annemarie Shepherd, Jordan E Eichholz, et al.
Cancer Medicine|May 7, 2020
Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumabNarek Shaverdian, Maria Thor, Annemarie F Shepherd, et al.
JCO Precision Oncology|October 6, 2022
Outcomes With Local Therapy and Tyrosine Kinase Inhibition in Patients With ALK/ROS1/RET-Rearranged Lung CancersHarper Hubbeling, Noura Choudhury, Jessica Flynn, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 4, 2020
Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumabMichael Offin, Narek Shaverdian, Andreas Rimner, et al.
Pageof 15